Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07296484 · ClinicalTrials.gov registry record · Phase 2

Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)

A Phase 2 study of Type 2 Diabetes and Cortisol Excess, sponsored by Sparrow Pharmaceuticals.

Recruiting
Registry status
Phase 2
Development phase
1,500
Enrollment target
20
Study locations

NCT07296484 is a Phase 2 study of Type 2 Diabetes and Cortisol Excess that is actively recruiting participants, run by Sparrow Pharmaceuticals. The registered enrollment target is 1,500 participants, above the 1,097-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (37% higher). The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07296484, a Phase 2 study of Type 2 Diabetes and Cortisol Excess, is actively recruiting participants, sponsored by Sparrow Pharmaceuticals.

RECRUITING
Registry status
Phase 2
Development phase
1,500 participants
Enrollment target
20
Study locations

Study Summary

CAPTAIN-T2D will take place in two parts. Part 1 (Screening) will evaluate patients with type 2 diabetes and elevated cortisol risk factors for trial eligibility and the presence of elevated cortisol. Participants deemed eligible from Part 1 will be randomized to either clofutriben or placebo in the double-blind (participant and investigator), dose-ranging, interventional Part 2 (Treatment).

Conditions Studied

Type 2 Diabetes Cortisol Excess

Interventions

  • DRUG Placebo
  • DRUG clofutriben

Study Locations (20)

California

  • Ark Clinical Research - Fountain Valley - Fountain Valley
  • Velocity Clinical Research, Huntington Park - Huntington Park
  • Velocity Clinical Research - Gardena - La Mesa
  • Ark Clinical Research - Long Beach - Long Beach
  • Los Angeles Institute for Metabolic Research - Los Angeles
  • Velocity Clinical Research, Los Angeles - Los Angeles
  • Amicis Research Center- Nordhoff - Northridge

Florida

  • Velocity Clinical Research, New Smyrna Beach - Edgewater
  • The Center for Diabetes and Endocrine Care - Fort Lauderdale
  • Admed Research LLC - Miami
  • Progressive Medical Research - Port Orange

Louisiana

  • Velocity Clinical Research, Lafayette - Lafayette
  • NOLA Care Clinical Research - Metairie
  • Tulane University School of Medicine - New Orleans

Arizona

  • Arizona Clinical Trials - Pecos - Chandler
  • Arizona Clinical Trials - Broadway - Tucson

Iowa

  • Velocity Clinical Research, Sioux City - Sioux City
  • Iowa Diabetes and Endocrinology Research Center - West Des Moines

Georgia

  • IACT Health-Brookstone Centre Pkwy - Columbus

Illinois

  • Chicago Clinical Research Institute - Chicago

Trial Details

FieldValue
Enrollment Target 1,500 participants
Start Date 2025-11-29
Est. Completion 2028-06-30
Phase Phase 2

Sponsor

Sparrow Pharmaceuticals

6 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07296484

The ClinicalTrials.gov registry entry for NCT07296484 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 1,500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 1,097-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (37% higher). The listed sponsor is Sparrow Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Type 2 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07296484 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Louisiana.

Frequently Asked Questions

What is clinical trial NCT07296484 about?

NCT07296484 is a clinical study titled "Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)". CAPTAIN-T2D will take place in two parts. Part 1 (Screening) will evaluate patients with type 2 diabetes and elevated cortisol risk factors for trial eligibility and the presence of elevated cortisol. Participants deemed eligible from Part 1 will be randomized to either clofutriben or placebo in the...

What is the current status of trial NCT07296484?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 1,500 participants. The study started on 2025-11-29. Estimated completion is 2028-06-30.

What conditions does trial NCT07296484 study?

This clinical trial studies the following conditions: Type 2 Diabetes, Cortisol Excess.

What interventions are being tested in trial NCT07296484?

The interventions under investigation include: Placebo (DRUG), clofutriben (DRUG).

Who is sponsoring clinical trial NCT07296484?

This trial is sponsored by Sparrow Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07296484 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Type 2 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Type 2 Diabetes

All registered trials for this condition

Cortisol Excess

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.